The question after the stroke
Can a peptide restore what ischemia took away? Dihexa and Cerebrolysin both claim neuroprotection. One is an experimental angiotensin IV analog. The other is a porcine brain peptide mixture used clinically in some countries. Which one has better evidence for post-stroke cognitive recovery?
Stroke leaves a cognitive deficit in most survivors. Executive function, memory, and processing speed often decline. Pharmacological options are limited. That gap drives interest in peptides that might promote synaptic repair or reduce secondary injury.
Dihexa: a small molecule with big binding claims
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic derivative of angiotensin IV. It was developed to cross the blood-brain barrier and bind hepatocyte growth factor (HGF) with high affinity. The proposed mechanism is activation of the HGF/c-Met pathway, which supports synaptogenesis and dendritic spine formation.
In a 2012 study, Dihexa improved spatial learning in scopolamine-impaired rats at doses far below those needed for other nootropics. The authors reported increased dendritic spine density in hippocampal slices. A 2018 follow-up showed Dihexa enhanced functional recovery after experimental stroke in rats, with reduced infarct volume and improved motor performance. But human data are absent. No clinical trial has been registered. No pharmacokinetic study in humans exists. The safety profile is unknown beyond acute rodent toxicity.
Evidence quality for Dihexa in post-stroke cognition: 1 of 5. It is a preclinical compound with promising mechanism but zero human validation.
Cerebrolysin: a clinical peptide mixture
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins. It has been used for decades in Europe and Asia for stroke, traumatic brain injury, and dementia. The proposed mechanisms include neurotrophic factor-like activity, reduced excitotoxicity, and promotion of neurogenesis.
Multiple randomized controlled trials have tested Cerebrolysin in acute ischemic stroke. A 2020 meta-analysis of nine trials (n=1,879) found Cerebrolysin improved global cognitive function at 90 days compared to placebo, with a standardized mean difference of 0.36 (95% CI 0.20 to 0.52). A 2023 Cochrane review concluded that Cerebrolysin may reduce death or dependency after stroke, but the certainty of evidence was low due to risk of bias and heterogeneity. For post-stroke cognitive impairment specifically, a 2022 systematic review reported improvements in Mini-Mental State Examination scores at 3 and 6 months, though effect sizes were modest.
Evidence quality for Cerebrolysin in post-stroke cognition: 3 of 5. Human trials exist, but many are small, industry-funded, or conducted in Eastern Europe with limited external validity.
Head-to-head: what can we actually compare?
No trial has directly compared Dihexa and Cerebrolysin. The comparison is indirect and asymmetrical. Cerebrolysin has a clinical evidence base. Dihexa has only animal data. That alone answers the question for most observers.
Mechanistically, they target different pathways. Dihexa is a selective HGF/c-Met agonist. Cerebrolysin is a pleiotropic mixture with multiple proposed actions. The latter may be more suited to the complex pathophysiology of stroke, where excitotoxicity, inflammation, and apoptosis all contribute. But pleiotropy also makes it harder to attribute benefit to a specific mechanism.
Safety profiles diverge sharply. Cerebrolysin has been administered to thousands of patients with rare serious adverse events, mostly injection site reactions or transient dizziness. Dihexa has no human safety record. Its long-term effects on HGF signaling, which is implicated in cancer progression, are unknown. That is a significant concern for a compound intended for chronic use.
Cost and access also differ. Cerebrolysin is a prescription drug in over 40 countries, though not approved by the FDA. Dihexa is sold as a research chemical by various online vendors, with no quality control or dosing standardization. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Where is each studied more?
Cerebrolysin research is concentrated in Eastern Europe, Russia, and China. Most trials are single-center and use varying doses (10 to 50 mL per day for 10 to 21 days). The lack of standardized protocols weakens meta-analytic conclusions. Dihexa research is almost entirely in academic labs in the United States, focused on Alzheimer's disease and Parkinson's models rather than stroke. Its stroke data come from one or two papers.
Could a future trial compare them? It would require a phase 1 study of Dihexa first, then a head-to-head against Cerebrolysin in a post-stroke population. That is at least five years away, assuming funding and regulatory approval. For now, the question remains open.
If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.